{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:23:53Z","timestamp":1793762633438,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01322-9","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T15:51:49Z","timestamp":1751557909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3380-5326","authenticated-orcid":false,"given":"Suheil Albert","family":"Atallah-Yunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-2952","authenticated-orcid":false,"given":"Matthew J.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Mwangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn L.","family":"Kuchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alnughmush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-9393","authenticated-orcid":false,"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-9132","authenticated-orcid":false,"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-0809","authenticated-orcid":false,"given":"Jose C.","family":"Villasboas Bisneto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-4808","authenticated-orcid":false,"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-6758","authenticated-orcid":false,"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"1322_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","volume":"34","author":"JR Cerhan","year":"2020","unstructured":"Cerhan JR. Epidemiology of follicular lymphoma. Hematol Oncol Clin North Am. 2020;34:631\u201346.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1322_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/hon.3138","volume":"41","author":"JW Friedberg","year":"2023","unstructured":"Friedberg JW. Update on follicular lymphoma. Hematol Oncol. 2023;41:43\u20137.","journal-title":"Hematol Oncol"},{"key":"1322_CR3","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/ajh.26737","volume":"97","author":"E Jacobsen","year":"2022","unstructured":"Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022;97:1638\u201351.","journal-title":"Am J Hematol"},{"key":"1322_CR4","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","volume":"402","author":"D Schrag","year":"2023","unstructured":"Schrag D, Beer TM, McDonnell CH 3rd, Nadauld L, Dilaveri CA, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251\u201360.","journal-title":"Lancet"},{"key":"1322_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/15592294.2019.1568178","volume":"14","author":"W Ding","year":"2019","unstructured":"Ding W, Chen G, Shi T. Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis. Epigenetics. 2019;14:67\u201380.","journal-title":"Epigenetics"},{"key":"1322_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745\u201359.","journal-title":"Ann Oncol"},{"key":"1322_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41586-022-05580-6","volume":"613","author":"N Loyfer","year":"2023","unstructured":"Loyfer N, Magenheim J, Peretz A, Cann G, Bredno J, Klochendler A, et al. A DNA methylation atlas of normal human cell types. Nature. 2023;613:355\u201364.","journal-title":"Nature"},{"key":"1322_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07466-6","volume":"9","author":"J Moss","year":"2018","unstructured":"Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018;9:5068.","journal-title":"Nat Commun"},{"key":"1322_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15:424\u201335.","journal-title":"Lancet Oncol"},{"key":"1322_CR10","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516\u201322.","journal-title":"Lancet"},{"key":"1322_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/bjh.13316","volume":"169","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC, Bilgrau AE, de Nully Brown P, Mylam KJ, Ahmad SA, Pedersen LM, et al. A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. Br J Haematol. 2015;169:435\u201344.","journal-title":"Br J Haematol"},{"key":"1322_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-210","volume":"12","author":"A Rueda","year":"2012","unstructured":"Rueda A, Casanova M, Redondo M, P\u00e9rez-Ruiz E, Medina-P\u00e9rez A. Has the time to come leave the \u201cwatch-and-wait\u201d strategy in newly diagnosed asymptomatic follicular lymphoma patients? BMC Cancer. 2012;12:210.","journal-title":"BMC Cancer"},{"key":"1322_CR13","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","volume":"30","author":"P Solal-C\u00e9ligny","year":"2012","unstructured":"Solal-C\u00e9ligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30:3848\u201353.","journal-title":"J Clin Oncol"},{"key":"1322_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/ajh.27504","volume":"100","author":"SA Atallah-Yunes","year":"2025","unstructured":"Atallah-Yunes SA, Rees MJ, Mwangi R, Kuchler RL, Nowakowski GS, Habermann TM, et al. Characteristics and outcomes of incidentally diagnosed diffuse large B-cell lymphoma and implications for cancer screening. Am J Hematol. 2025;100:158\u201362.","journal-title":"Am J Hematol"},{"key":"1322_CR15","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","volume":"30","author":"JW Friedberg","year":"2012","unstructured":"Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012;30:3368\u201375.","journal-title":"J Clin Oncol"},{"key":"1322_CR16","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/ije\/dyx119","volume":"46","author":"JR Cerhan","year":"2017","unstructured":"Cerhan JR, Link BK, Habermann TM, Maurer MJ, Feldman AL, Syrbu SI, et al. Cohort Profile: the Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. Int J Epidemiol. 2017;46:1753\u20134i.","journal-title":"Int J Epidemiol"},{"key":"1322_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0066-x","volume":"2","author":"DA Ahlquist","year":"2018","unstructured":"Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. NPJ Precis Oncol. 2018;2:23.","journal-title":"NPJ Precis Oncol"},{"key":"1322_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/ajh.27533","volume":"100","author":"TE Witzig","year":"2025","unstructured":"Witzig TE, Taylor WR, Mahoney DW, Bamlet WR, Foote PH, Burger KN, et al. Blood plasma methylated DNA markers in the detection of lymphoma: discovery, validation, and Clinical Pilot. Am J Hematol. 2025;100:218\u201328.","journal-title":"Am J Hematol"},{"key":"1322_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1470-2045(23)00277-2","volume":"24","author":"BD Nicholson","year":"2023","unstructured":"Nicholson BD, Oke J, Virdee PS, Harris DA, O\u2019Doherty C, Park JE, et al. Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study. Lancet Oncol. 2023;24:733\u201343.","journal-title":"Lancet Oncol"},{"key":"1322_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.amjmed.2021.09.012","volume":"135","author":"T Olivier","year":"2022","unstructured":"Olivier T, Gill J, Prasad V. Multi-cancer screening tests: communicating about risks should be prioritized. Am J Med. 2022;135:413\u20135.","journal-title":"Am J Med"},{"key":"1322_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJMp2400297","volume":"391","author":"HA Robbins","year":"2024","unstructured":"Robbins HA. Multicancer early detection tests\u2014keeping a high bar for evidence of benefit. N. Engl J Med. 2024;391:292\u20134.","journal-title":"N. Engl J Med"},{"key":"1322_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jamainternmed.2023.3781","volume":"183","author":"HG Welch","year":"2023","unstructured":"Welch HG, Dey T. Testing whether cancer screening saves lives: implications for randomized clinical trials of multicancer screening. JAMA Intern Med. 2023;183:1255\u20138.","journal-title":"JAMA Intern Med"},{"key":"1322_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1470-2045(24)00645-4","volume":"26","author":"L Nadauld","year":"2025","unstructured":"Nadauld L, McDonnell CH 3rd, Dilaveri CA, Klein EA, Reid R, et al. Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study. Lancet Oncol. 2025;26:165\u201374.","journal-title":"Lancet Oncol"},{"key":"1322_CR24","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055\u201365.","journal-title":"Lancet Oncol"},{"key":"1322_CR25","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11:e593\u2013e605.","journal-title":"Lancet Haematol"},{"key":"1322_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143:496\u2013506.","journal-title":"Blood"},{"key":"1322_CR27","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"Elsallab","year":"2024","unstructured":"Elsallab, Ellithi M, Lunning MA M, D\u2019Angelo, Ma C, Perales MA J, et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood. 2024;143:2099\u2013105.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01322-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01322-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01322-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T15:51:49Z","timestamp":1751557909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01322-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1322"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01322-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with relevant guidelines and regulations. This study was approved by the Mayo Clinic Institutional Review Board (IRB #23-007912). Informed consent was obtained from all participants enrolled in the Molecular Epidemiology Resource cohort.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"116"}}